The effect of statins on psoriasis severity: a meta-analysis of randomized clinical trials

Mateusz Socha; Aldona Pietrzak; Ewelina Grywalska; Daniel Pietrzak; Dariusz Matosiuk; Paweł Kiciński; Jacek Rolinski

doi:10.5114/aoms.2019.90343

The effect of statins on psoriasis severity: a meta-analysis of randomized clinical trials

Arch Med Sci. 2019 Dec 6;16(1):1-7. doi: 10.5114/aoms.2019.90343. eCollection 2020.

Authors

Mateusz Socha¹, Aldona Pietrzak², Ewelina Grywalska³, Daniel Pietrzak⁴, Dariusz Matosiuk⁵, Paweł Kiciński⁶, Jacek Rolinski³

Affiliations

¹ Department of Internal Medicine and Cardiology, 1 Military Clinical Hospital, Lublin, Poland.
² Department of Dermatology, Venereology and Pediatric Dermatology, Medical University of Lublin, Lublin, Poland.
³ Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, Lublin, Poland.
⁴ Department of Anaesthesiology and Intensive Care, Medical University of Lublin, Lublin, Poland.
⁵ Department of Synthesis and Chemical Technology of Pharmaceutical Substances, Medical University of Lublin, Lublin, Poland.
⁶ Department of Experimental Hematooncology, Medical University of Lublin, Lublin, Poland.

Abstract

Introduction: Statins may reduce the severity of psoriasis, but the available evidence is unclear. We conducted a meta-analysis of randomized controlled studies (RCTs) that investigated the effect of statins on psoriasis severity assessed with the Psoriasis Area and Severity Index (PASI).

Material and methods: Two investigators searched independently the following databases: Medline, EMBASE, Cochrane Central Register of Controlled Trials and ClinicalTrials.gov from inception to February 2019. Additionally, reference lists from all available articles were searched manually. We included only RCTs carried out among adult (≥ 16 years) patients with psoriasis who received oral statins for ≥ 8 weeks and had psoriasis severity assessed with the PASI at baseline and at the end of follow-up. We used random effects meta-analysis to calculate the mean difference (D) in PASI change between patients who received either a statin or a comparator.

Results: Of 279 records identified, there were 5 eligible RCTs, with a total of 223 patients, including 128 patients who received a statin (atorvastatin or simvastatin). The improvement in psoriasis severity (PASI) was significantly greater in patients who received statins than in those who received comparators (D = 2.76, 95% CI: 0.49-5.04, p = 0.017). In subgroup analyses, the improvement in PASI values was significant for simvastatin (D = 3.70, 95% CI: 2.52-4.89, p < 0.001) but not for atorvastatin (D = 2.30, 95% CI: -1.28-5.88, p = 0.210).

Conclusions: Oral statins may improve psoriasis, particularly in patients with severe disease. This observation should be verified in long-term, well-designed studies that will enable analyses adjusted for clinical variables.

Keywords: atorvastatin; hydroxymethylglutaryl-CoA reductase inhibitors; psoriasis; simvastatin.